Book Value per Share: BeyondSpring (BYSI)

Public company logo of BeyondSpring, Inc. (BYSI)

The dynamics of capital per share demonstrate the evolution of BeyondSpring Inc. (BYSI) assets in its drive to expand markets for neutropenia drugs. The value of -0.86 determines the latest valuation metric. Stability is ensured by the strong pricing power of plinabulin, while structural flexibility is maintained through the full outsourcing of manufacturing and clinical trials.

BYSI - BeyondSpring, Inc. Book Value of One Share over the range 07/04/2022 - 10/26/2026

Summary analytical data breakdowns for beyondspringpharma.com (BYSI)

- price and consensus price forecast:
Price Chart BeyondSpring Pharma|BYSI - Analyst Median Target
- market capitalization data:
Market Capitalization BeyondSpring Inc.|BYSI - Company Buyout Price
- book capitalization data:
Book Value per Share BeyondSpring|BYSI - Book Value of Business|Market Capitalization to Book Value Ratio beyondspringpharma.com|BYSI - Company Assets
- debt and liquidity data:
Debt to Equity BeyondSpring Inc.|BYSI - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital BeyondSpring|BYSI - Company Cumulative Debt|Debt to Book Capitalization Ratio BeyondSpring Inc.
Fundamental company valuation:BYSI BeyondSpring Pharma
Manufactured product of beyondspringpharma.com

Book value per share reflects the portion of equity attributable to a single security, allowing for an assessment of the business's intrinsic value net of all liabilities. By analyzing the historical book value per share chart, investors determine the asset's margin of safety, which is critical for BeyondSpring Inc. (BYSI) due to stringent government price regulations on pharmaceuticals in China.

Competitors of BeyondSpring Inc. (BYSI)

Net Assets per Single Share INCY (Incyte Corp.)|HCM - Net Assets per Share|Nuvation Bio Inc. - Book Value per Share|dayonebio.com (DAWN) - Net Assets per Share|Monopar Therapeutics Inc. - Book Value per Share|Book Value of One Share Inhibrx|I-Mab - Book Value per Share|Net Asset Value per Share FENC (Fennec)|HRTX - Net Assets per Single Share|Equity per Share nuvectis.com NVCT|CHRS (Coherus Biosciences) - Book Value per Share|CRBP: Net Asset Value per Share|Net Assets per Single Share cardiffoncology.com CRDF|BioAtla (BCAB) - Accounting Value of a Share|LIXT (Lixte Biotechnology) - Book Value per Share|Book Value per Share CTXR|Net Assets per Single Share Cellectar Biosciences, Inc. (CLRB)|Net Assets per Single Share BioLineRx Ltd BLRX|Accounting Value per Share Can-Fite BioPharma, Ltd.|Aprea Therapeutics Inc. - Accounting Value of a Share|KZIA (Kazia) - Net Assets per Single Share|SLXN: Net Asset Value per Share|Net Assets per Single Share nucana.com|Chimerix Inc. (CMRX) - Equity per Share|Book Value per Share CYCC|Accounting Value per Share GTHX|Kronos Bio, Inc. - Net Assets per Single Share|Net Asset Value per Share KTRA (kintara.com)|Net Assets per Single Share Oncternal Therapeutics, Inc. ONCT|Portage Biotech Inc - Net Assets per Single Share